Method for treating skin cancer

Patent metadata

Field	Value
Publication number	US-10869854-B2
Application number	US-201916681379-A
Country	US
Kind code	B2
Filing date	Nov 12, 2019
Priority date	Jul 26, 2012
Publication date	Dec 22, 2020
Grant date	Dec 22, 2020

Abstract

A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

First claim

What is claimed and desired to be secured by Letters Patent of the United States is:

1. A method for treating skin cancer, comprising the step(s) of:
administering a surfactant or a pharmaceutically acceptable salt thereof to a patient having skin cancer, wherein the protonated form of the surfactant is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and cyano group containing 1 to approximately 25 carbon atom(s); wherein R 2 is NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H, OH, and an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and/or cyano group containing 1 to approximately 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and/or cyano group containing approximately 8 to approximately 25 carbon atom(s).

2. The method for treating skin cancer according to claim 1 , further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.

3. The method for treating skin cancer according to claim 1 , wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma, squamous cell carcinoma, melanoma, and merkel cell carcinoma.

4. A method for treating skin cancer, comprising the step(s) of:
administering a surfactant or a pharmaceutically acceptable salt thereof to a patient having skin cancer, wherein the protonated form of the surfactant is represented by the following chemical structure:

wherein X comprises an integer ranging from approximately 2 to approximately 16, and wherein Y comprises an integer ranging from approximately 6 to approximately 16.

5. The method for treating skin cancer according to claim 4 , further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.

6. The method for treating skin cancer according to claim 4 , wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma, squamous cell carcinoma, melanoma, and merkel cell carcinoma.

7. A method for treating skin cancer, comprising the step(s) of:
administering a surfactant or a pharmaceutically acceptable salt thereof to a patient having skin cancer, wherein the surfactant is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and/or cyano group containing 1 to approximately 25 carbon atom(s); wherein R 2 is NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H, OH, and an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and/or cyano group containing 1 to approximately 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl, aryl, alkoxy, alkanoyl, aroyl, alkenyl, and/or cyano group containing approximately 8 to approximately 25 carbon atom(s), and wherein X is a counter cation.

8. The method for treating skin cancer according to claim 7 , further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.

9. The method for treating skin cancer according to claim 7 , wherein the skin cancer is selected from one of the groups comprising basal cell carcinoma, squamous cell carcinoma, melanoma, and merkel cell carcinoma.

Assignees

• Silver Michael E
• The William M Yarbrough Found

Inventors

• Silver Michael E

Classifications

• A61K31/198

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K31/26 Primary

  Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters · CPC title